NCT04360785View on ClinicalTrials.gov

Effect of Two Methotrexate in Sync With the First Adalimumab to Prevent the Immunisation Anti Ada in Spondyloarthritis

NACompletedINTERVENTIONAL
Enrollment

124

Participants

Timeline

Start Date

November 11, 2020

Primary Completion Date

September 13, 2022

Study Completion Date

February 27, 2023

Conditions
Spondyloarthritis
Interventions
DRUG

Methotrexate

Patients randomized in this arm will have one subcutaneous injection of methotrexate 15min before and one 24h after their first injection of adalimumab prescribed as usual

Trial Locations (17)

Unknown

Hopital Pellegrin, Bordeaux

Hopital Ambroise Paré, Boulogne-Billancourt

Hopital La Cavale Blanche, Brest

CHU Trousseau, Chambray-lès-Tours

CH Sud Francilien, Corbeil-Essonnes

Hopital Mondor, Créteil

Kremlin Bicetre hospital, Le Kremlin-Bicêtre

CH Le Mans, Le Mans

Hopital Saint Philibert, Lille

CHU Nantes, Nantes

CHR Orléans, Orléans

Hopital Bichat, Paris

Hopital Cochin, Paris

Hopital la Pitié Salpétrière, Paris

Hopital Saint Antoine, Paris

CH Pontoise, Pontoise

CHU Rouen, Rouen

All Listed Sponsors
lead

Assistance Publique - Hôpitaux de Paris

OTHER

NCT04360785 - Effect of Two Methotrexate in Sync With the First Adalimumab to Prevent the Immunisation Anti Ada in Spondyloarthritis | Biotech Hunter | Biotech Hunter